Urteste S.A. (WSE:URT)

Poland flag Poland · Delayed Price · Currency is PLN
37.80
+2.80 (8.00%)
At close: Dec 5, 2025
-52.87%
Market Cap 53.29M
Revenue (ttm) 1.80M
Net Income (ttm) -5.47M
Shares Out 1.41M
EPS (ttm) -3.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,727
Average Volume 2,482
Open 35.90
Previous Close 35.00
Day's Range 35.50 - 38.60
52-Week Range 24.00 - 106.00
Beta -0.34
RSI 50.97
Earnings Date Nov 28, 2025

About Urteste

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, stomach, lung, oesophagus, ovary, endometrium, blood, breast, and nervous system cancer. The company was incorporated in 2021 and is based in Gdansk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 20
Stock Exchange Warsaw Stock Exchange
Ticker Symbol URT
Full Company Profile

Financial Performance

In 2024, Urteste's revenue was 1.80 million, an increase of 35.34% compared to the previous year's 1.33 million. Losses were -3.63 million, -35.00% less than in 2023.

Financial Statements

News

There is no news available yet.